Compare Symbotic Inc (SYM) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Symbotic Inc vs GeneDx Holdings Corp — how do they compare? Symbotic Inc trades at $42.89 (market cap $5.19B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: Symbotic Inc is far larger — about 2.9× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Symbotic Inc nearer its low. Which is the better fit depends on your goals.
| SYM | WGS | |
|---|---|---|
Market Cap | $5.19B | $1.80B |
Sector | Technology | Technology |
52-Week High | $87.30 | $167.51 |
52-Week Low | $38.57 | $34.51 |
Enterprise Value | $3.18B | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Symbotic (SYM) trades at $40.83, down 1.02% recently, with a bearish technical signal and key support at $40. The company reported revenue of $2.25 billion in 2025 but a net loss of $16.94 million, though gross margins improved to 20.43%. Recent news highlights its acquisition of ARMS Innovations and upcoming Q3 2026 earnings on August 5, 2026, amid growing interest in warehouse automation.
Analyst consensus is bullish with a $57.50 price target, but risks include persistent net losses, high EV/EBITDA of 219.3, and competitive pressures. The stock offers growth potential from AI-driven warehouse automation demand, yet profitability challenges and market volatility pose significant headwinds for investors.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% amid a bearish technical signal and negative profitability. Recent earnings showed a Q1 2026 miss after two prior beats, with revenue growth but widening losses projected for 2026. The stock faces significant headwinds from multiple securities class action lawsuits alleging misrepresentations, with a deadline of August 3, 2026.
Despite a high analyst buy consensus (90.9%) and a $75.40 price target implying 24% upside, risks are elevated due to litigation, negative margins, and a high EV/EBITDA of 161.17. The upcoming Q2 2026 results on August 3 will be critical for investor confidence, but the legal overhang and fundamental challenges suggest cautious near-term outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
